Drugs for Pik3ca-Related Overgrowth Spectrum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 64)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Teriflunomide |
Approved |
Phase 4 |
|
108605-62-5, 163451-81-8 |
54677977 54684141 |
Synonyms:
(Z)-2-CYANO-ALPHA,ALPHA,ALPHA-TRIFLUORO-3-HYDROXY-P-CROTONOTOLUIDIDE
A 771726
A 77-1726
A77 1726
A77 1726|Aubagio®|flucyamide|HMR-1726
A771726
AUBAGIO
FLUCYAMIDE
HMR 1726
|
HMR1726
HMR-1726
LEFLUNOMIDE RELATED COMPOUND B
LEFLUNOMIDE RELATED COMPOUND B RS
TERIFLUNOMIDA
TERIFLUNOMIDE
TÉRIFLUNOMIDE
TERIFLUNOMIDUM
|
|
2 |
|
Ocrelizumab |
Approved, Investigational |
Phase 4 |
|
637334-45-3 |
|
Synonyms:
2H7
2H7|Ocrevus®|PRO70769|RG1594
OCRELIZUMAB
Ocrelizumab (genetical recombination)
OCREVUS
|
PR-070769
R-1594
RG-1594
rhuMAb 2H7
|
|
3 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260 |
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(−)-arterenol
(-)-Arterenol
(−)-noradrenaline
(-)-Noradrenaline
(−)-norepinephrine
(-)-Norepinephrine
(-)-norepinephrine|Levarterenol®|noradrenaline
(R)-(−)-norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol
(R)-noradrenaline
(R)-norepinephrine
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]PYROCATECHOL
Adrenor
Aktamin
Arterenol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
|
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-Arterenol
Levarterenol
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
L-noradrenaline
L-Norepinephrine
Noradrenalin
Noradrenaline
Nor-adrenaline
Norartrinal
Norepinefrina
Norepinephrine
Norépinéphrine
Norepinephrinum
Norepirenamine
Nor-epirenan
R-NOREPINEPHRINE
Sympathin E
|
|
4 |
|
Octreotide |
Approved, Investigational |
Phase 4 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
5 |
|
Midodrine |
Approved |
Phase 4 |
|
133163-28-7, 42794-76-3 |
4195 |
Synonyms:
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(b-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
(±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-b-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-β-hydroxyphenethyl)acetamide
A-4020 LINZ
Amatine
Cahill may roberts brand OF midodrine monohydrochloride
Christiaens brand OF midodrine monohydrochloride
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(b-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(Β-hydroxy-2,5-dimethoxyphenethyl)glycinamid
|
Gutron
Midodrin
Midodrina
Midodrine
Midodrine HCL
Midodrine hydrochloride
Midodrine monohydrochloride
Midodrinum
Midon
Monohydrochloride, midodrine
Nycomed brand OF midodrine monohydrochloride
ProAmatine
Shire brand OF midodrine monohydrochloride
ST 1085
ST-1085
|
|
6 |
|
Analgesics |
|
Phase 4 |
|
|
|
7 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
8 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
9 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
10 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
11 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
12 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
13 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
15 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
16 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
17 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
18 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
19 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
20 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
21 |
|
Tacrolimus |
Approved, Investigational |
Phase 3 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
22 |
|
Methyltestosterone |
Approved |
Phase 2, Phase 3 |
|
58-18-4 |
6010 |
Synonyms:
17 alpha Methyltestosterone
17 beta Hydroxy 17 methyl 4 androsten 3 one
17 beta Methyltestosterone
17 beta-Hydroxy-17-methyl-4-androsten-3-one
17 beta-Methyltestosterone
17 Epimethyltestosterone
17(a)-Methyl-delta(4)-androsten-17(b)-ol-3-one
17(a)-Methyl-δ(4)-androsten-17(b)-ol-3-one
17(alpha)-Methyl-Delta(4)-androsten-17(beta)-ol-3-one
17(Α)-methyl-δ(4)-androsten-17(β)-ol-3-one
17alpha Methyl testosterone
17alpha Methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-Delta(4)-androsten-17beta-ol-3-one
17alpha-Methyl-delta-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-Methyl-testosterone
17-alpha-Methyltestosterone
17a-Methyl-3-oxo-4-androsten-17b-ol
17a-Methyl-delta(4)-androsten-17b-ol-3-one
17a-Methyltestosterone
17a-Methyl-δ(4)-androsten-17b-ol-3-one
17beta Hydroxy 17 methyl 4 androsten 3 one
17beta Methyltestosterone
17beta-Hydroxy-17-methyl-4-androsten-3-one
17beta-Hydroxy-17-methylandrost-4-en-3-one
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17beta-Methyltestosterone
17b-Hydroxy-17-methylandrost-4-en-3-one
17-b-Hydroxy-17-methylandrost-4-en-3-one
17-Epimethyltestosterone
17-Methyltestosterone
17Α-methyl-3-oxo-4-androsten-17β-ol
17Α-methyltestosterone
17Α-methyl-δ(4)-androsten-17β-ol-3-one
17Α-METHYL-Δ4-ANDROSTEN-17Β-OL-3-ONE
17Β-hydroxy-17-methylandrost-4-en-3-one
17-Β-hydroxy-17-methylandrost-4-en-3-one
4-Androstene-17alpha-methyl-17beta-ol-3-one
4-Androstene-17a-methyl-17b-ol-3-one
|
4-Androstene-17α-methyl-17β-ol-3-one
Android
Android (methyltestoterone)
Android 10
Android 25
Android 5
Android-10
Android-25
Android-5
CDB-110
Global pharmaceutical brand OF methyltestosterone
ICN brand 1 OF methyltestosterone
ICN brand 2 OF methyltestosterone
L 589.372
L-589.372
L-589372
Mesteron
Mesterone
Metandren
Methitest
Methyltestosterone
METHYLTESTOSTERONE CIII
Methyltestosteronum
Metiltestosterona
NSC-139965
NSC-9701
Oreton
ORETON METHYL
PERANDREN
PLEX HORMONE
POTENSAN FTE
RU 24400
RU-24400
Schering brand OF methyltestosterone
Star brand OF methyltestosterone
Testoviron
TESTOVIS
Testred
U-2842
Virilon
|
|
23 |
|
Testosterone undecanoate |
Approved, Investigational |
Phase 2, Phase 3 |
|
5949-44-0 |
21873174 65157 |
Synonyms:
2,15-Dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl undecanoic acid
ANDRIOL
AVEED
JATENZO
MK-3033
NEBIDO
ORG-538
RESTANDOL
|
RESTANDOL TESTOCAP
Testosterone undecanoate
Testosterone undecanoic acid
Testosterone undeconate
Testosterone undecylate
TSX-011
UNDESTOR
|
|
24 |
|
Testosterone enanthate |
Approved |
Phase 2, Phase 3 |
|
315-37-7 |
9416 |
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
17beta-Hydroxyandrost-4-en-3-one heptanoate
17beta-Hydroxyandrost-4-en-3-one heptanoic acid
17b-Hydroxyandrost-4-en-3-one heptanoate
17b-Hydroxyandrost-4-en-3-one heptanoic acid
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17Β-hydroxyandrost-4-en-3-one heptanoate
17Β-hydroxyandrost-4-en-3-one heptanoic acid
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn l.a.
Andropository
Androtardyl
Atlatest
BTG Brand OF testosterone enanthate
DEA no. 4000
Delatest
Delatestryl
DePatestrye
depo-testro Med
Ditate
Durathate
eifelfango Brand OF testosterone enanthate
Everone
Exten test
Jenapharm brand OF testosterone enanthate
Malogen l.a.
Malogen l.a.200
NSC-17591
Orquisteron-e
Pasadena brand OF testosterone enanthate
Primoteston depot
|
Primotestone
reposo TMD
Roberts brand OF testosterone enanthate
Rotexmedica brand OF testosterone enanthate
Rugby brand OF testosterone enanthate
Schering brand OF testosterone enanthate
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosteron depot-rotexmedica
Testosteron-depot eifelfango
Testosteron-depot jenapharm
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone 17-enanthate
Testosterone 17-enanthic acid
Testosterone enantate
Testosterone enanthate
TESTOSTERONE ENANTHATE CIII
Testosterone enanthic acid
Testosterone heptanoate
Testosterone heptanoic acid
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
Testrin p.a.
Theramed brand OF testosterone enanthate
Theramex
XYOSTED (AUTOINJECTOR)
|
|
25 |
|
Testosterone |
Approved, Investigational |
Phase 2, Phase 3 |
|
58-22-0 |
5408 6013 |
Synonyms:
(+-)-8-ISO-TESTOSTERONE
(+-)-RETROTESTOSTERONE
(+)-TESTOSTERONE
(+-)-TESTOSTERONE
(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE
(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
13-ISO-TESTOSTERONE
17 beta Hydroxy 4 androsten 3 one
17 beta Hydroxy 8 alpha 4 androsten 3 one
17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17A-HYDROXY-13A-ANDROST-4-EN-3-ONE
17A-HYDROXY-14B-ANDROST-4-EN-3-ONE
17A-HYDROXY-ANDROST-4-EN-3-ONE
17-beta-Hydroxy-4-androsten-3-one
17BETA-HYDROXY-4-ANDROSTEN-3-ONE
17-beta-Hydroxy-8 alpha-4-androsten-3-one
17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-13A-ANDROST-4-EN-3-ONE
17b-Hydroxy-4-androsten-3-one
17B-HYDROXY-8A-ANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ON
17B-HYDROXYANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ONE
17B-HYDROXYANDROST-4-ENE-3-ONE
17B-HYDROXY-D4-ANDROSTEN-3-ONE
17B-TESTOSTERONE
17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
17-HYDROXY-ANDROST-4-EN-3-ONE
17-HYDROXY-D4-ANDROSTEN-3-ONE
17Β-hydroxy-4-androsten-3-one
4-ANDROSTEN-17BETA-OL-3-ONE
4-Androsten-17b-ol-3-one
4-ANDROSTEN-17Β-OL-3-ONE
4-ANDROSTEN-3-ONE-17B-OL
8 Isotestosterone
8-Isotestosterone
8-ISO-TESTOSTERONE
9B,10A-TESTOSTERONE
9B-TESTOSTERONE
Andriol
Andro
Andro 100
Andro L.A. 200
ANDRODERM
Androderm®|Delatestryl®
ANDROGEL
ANDROGEL 1%
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
ANDROPATCH
Andropository 200
Androsorb
ANDROST-4-EN-17B-OL-3-ONE
ANDROST-4-ENE-17B-OL-3-ONE
Androtop
Andrusol
Andryl 200
AstraZeneca brand OF testosterone
Auxilium pharmaceuticals inc. brand OF testosterone
AXIRON
Bartor brand OF testosterone
Beta Testosterone
Bio-T-Gel
CDB 111C
CEPA brand OF testosterone
Cristerona T
Cristerone T
D4-ANDROSTEN-17B-OL-3-ONE
Dea No. 4000
Delatest
DELATESTRYL
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
Dr. kade brand OF testosterone
Epitestosteron
Everone 200
Faulding brand OF testosterone
Ferring brand OF testosterone
FORTESTA
Geno-cristaux gremy
GlaxoSmithKline brand OF testosterone
Hauck brand OF testosterone
Histerone
Homosteron
Homosterone
INTRINSA
Libigel
LUMITESTOSTERON
|
Malerone
Malestrone
Malogen in Oil
Malogen, Aquaspension Injection
MERTESTATE
Metandren
Methyltestosterone
NATESTO
Neo-Hombreol F
Neotestis
Neo-Testis
NSC-9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Ortho brand OF testosterone
Paladin brand OF testosterone
Pasadena brand OF testosterone
Perandren
Percutacrine androgenique
Primotest
Primoteston
RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE
Relibra
RETROTESTOSTERONE
Scheinpharm Testone-Cyp
Schering brand OF testosterone
SmithKline beecham brand OF testosterone
Solvay brand OF testosterone
Sterotate
STRIANT
STRIANT SR
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
TESTIM
TESTIM 1%
Testobase
TESTODERM
TESTODERM TTS
TESTOGEL
Testoject-50
Testolent
Testolin
TESTOPATCH
TESTOPEL
Testopel Pellets
Testopropon
TESTORAL
Testosteroid
TESTOSTERON
TESTOSTERONA
Testosterona [INN-Spanish]
TESTOSTERONE
TESTOSTÉRONE
TESTOSTERONE CIII
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone sulfate
TESTOSTERONUM
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro aq
TESTRONE
Testryl
TOSTRAN
Tostrelle
Tostrex
Trans-Testosterone
Ulmer brand OF testosterone
Unimed brand OF testosterone
Viatrel
Virilon
Virilon IM
Virormone
VIROSTERONE
VOGELXO
Watson brand OF testosterone
|
|
26 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 3 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
27 |
|
Acyline |
Investigational |
Phase 2, Phase 3 |
|
170157-13-8 |
44208979 |
Synonyms:
|
28 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
29 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
30 |
|
Calcineurin Inhibitors |
|
Phase 3 |
|
|
|
31 |
|
Anabolic Agents |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Hormone Antagonists |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Androgens |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Testosterone 17 beta-cypionate |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
37 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
38 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
39 |
|
Pravastatin |
Approved |
Phase 2 |
|
81093-37-0 |
54687 |
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
3beta-Hydroxycompactin
Apo pravastatin
Apo-pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C10AA03
Compactin
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
Juste brand OF pravastatin sodium
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
Lipostat®|Pravachol®|pravastatin sodium
Mevalothin
Mevalotin
Mevastatin
Mevinolin
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
|
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
PRAVASTATIN
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin sodium salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
RMS 431
RMS-431
Sankyo brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
Squibb brand OF pravastatin sodium
Vasten
|
|
40 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
41 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
42 |
|
Antifungal Agents |
|
Phase 2 |
|
|
|
43 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
44 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
45 |
|
Hypolipidemic Agents |
|
Phase 2 |
|
|
|
46 |
|
Anticholesteremic Agents |
|
Phase 2 |
|
|
|
47 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 2 |
|
|
|
48 |
|
Lipid Regulating Agents |
|
Phase 2 |
|
|
|
49 |
|
Pregabalin |
Approved, Investigational |
|
|
148553-50-8 |
5486971 |
Synonyms:
(R-)-3-Isobutyl gaba
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S)-PREGABALIN
(S+)-3-isobutyl gaba
3 Isobutyl gaba
3-(Aminomethyl)-5-methylhexanoic acid
3-Isobutyl gaba
ALZAIN
AXALID
CI 1008
CI-1008
|
GABA, 3-isobutyl
LECAENT
Lyrica
LYRICA CR
NERVALIN
PD 144723
PD-144723
PREGABALIN
Pregabalina
REWISCA
S-(+)-3-ISOBUTYLGABA
YNP-1807
|
|
50 |
|
Interferon beta-1b |
Approved |
|
|
145155-23-3 |
|
Synonyms:
BETASERON
EXTAVIA
FIBROBLAST INTERFERON
IFN BETA 1B
IFN-BETA
Interferon beta 1b (recombinant)
|
INTERFERON BETA PRECURSOR
INTERFERON BETA-1B
Interferon beta-1b,recombinant
Interferon-beta-1b
Recombinant interferon beta-1b
|
|
Interventional clinical trials:
(show all 47)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients |
Completed |
NCT01895335 |
Phase 4 |
Teriflunomide |
2 |
An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis |
Completed |
NCT03589105 |
Phase 4 |
Ocrelizumab 300 mg;Ocrelizumab 600 mg |
3 |
Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. |
Completed |
NCT03455322 |
Phase 4 |
norepinephrine versus midodrine & octreotide |
4 |
Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt. |
Completed |
NCT00817206 |
Phase 3 |
LCP-Tacro;Prograf |
5 |
Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2) |
Completed |
NCT01327495 |
Phase 2, Phase 3 |
Testosterone 1% gel 1.25 g;Testosterone 1% gel 2.5 g;Testosterone 1% gel 5.0 g;testosterone 1% gel 10 g;testosterone 1% gel 15 g;Acyline |
6 |
Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant |
Completed |
NCT01187953 |
Phase 3 |
Prograf (tacrolimus);LCP-Tacro |
7 |
Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation |
Completed |
NCT02428296 |
Phase 2 |
Sirolimus |
8 |
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study |
Completed |
NCT00828308 |
Phase 2 |
Ixabepilone |
9 |
EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) |
Recruiting |
NCT04589650 |
Phase 2 |
Alpelisib;Placebo |
10 |
Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life |
Recruiting |
NCT04356209 |
Phase 2 |
Pravastatin |
11 |
A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies |
Active, not recruiting |
NCT04980872 |
Phase 2 |
Miransertib |
12 |
A Phase II Study to Evaluate the Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) |
Active, not recruiting |
NCT04980833 |
Phase 2 |
Alpelisib |
13 |
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC) |
Terminated |
NCT03094832 |
Phase 1, Phase 2 |
Miransertib |
14 |
PROS Brief Smoking Cessation Counseling in Pediatric Practice to Reduce Secondhand Smoke Exposure of Young Children |
Completed |
NCT00135213 |
Phase 1 |
|
15 |
(COMEBACK): Biktarvy in PLWH But Not Retained in Care Coupled With a Strengths-based Case Management Approach to Assess Virologic Suppression Rates and Retention in Care, Along With Patient Reported Outcomes (PROS). |
Unknown status |
NCT04519970 |
|
|
16 |
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Have Received Alpelisib as Part of a Compassionate Use Program (EPIK-P1) |
Completed |
NCT04285723 |
|
|
17 |
Home-based Assessment of Patient Reported Outcome (PROs) Measures in Sickle Cell Disease (SCD) Using A Smartphone App Platform: A Feasibility Study |
Completed |
NCT04678037 |
|
|
18 |
Pros and Cons of Botulinum Injection Treatment in Cerebral Palsy: A Qualitative Study Examining the Caregiver's Perspectives |
Completed |
NCT04256187 |
|
|
19 |
Patient-reported-outcomes(PROs) in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin in Primary Care Settings |
Completed |
NCT02273908 |
|
|
20 |
US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBETAapp™ in Patients With Multiple Sclerosis Treated With BETASERON® Using BETACONNECT™ Autoinjector |
Completed |
NCT04356339 |
|
Interferon-beta-1b (BETASERON, BAY 86-5046) |
21 |
Assessing Behavioral, Functional, and Clinical Patient-Reported Outcomes (PROs) in Subjects Diagnosed With COVID-19 |
Completed |
NCT05042232 |
|
|
22 |
The Biosensor Study: Exploratory Study Evaluating the Use of Wearable Biosensors and Patient Reported Outcomes (PROs) to Assess Performance Status and Distress in Patients With Cancer |
Completed |
NCT02659358 |
|
|
23 |
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs). |
Completed |
NCT02588053 |
|
|
24 |
A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA) |
Completed |
NCT02506179 |
|
|
25 |
A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A |
Completed |
NCT02396862 |
|
Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222) |
26 |
The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients |
Completed |
NCT01601119 |
|
Rebif |
27 |
A Usability Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record |
Completed |
NCT01024166 |
|
|
28 |
CVC Pros and Cons of Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study |
Completed |
NCT00250809 |
|
|
29 |
Providing Resources to Enhance Patients' Readiness to Make Decisions About Kidney Disease: Partnering to Break the News, Review All Options, Weigh Pros and Cons (PREPARE NOW) |
Completed |
NCT02428569 |
|
|
30 |
A Qualitative Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record |
Completed |
NCT00878267 |
|
|
31 |
Prospective Epidemiological Study to Determine the Variation in the Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer (PROS-PROSQoLI Study) |
Completed |
NCT02853409 |
|
|
32 |
Health-related Quality of Life, Symptom Severity, and Pain Among Patients Treated With Alpelisib for PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study |
Recruiting |
NCT05294289 |
|
|
33 |
The Phenotype and Etiology of Proteus Syndrome |
Recruiting |
NCT00001403 |
|
|
34 |
Prospective Evaluation of Patient Reported Outcomes and Satisfaction With Education in Breast Cancer Patients (PROS) |
Recruiting |
NCT03333122 |
|
|
35 |
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice |
Recruiting |
NCT03850912 |
|
|
36 |
A Pilot Study to Define PROs for Establishing a Pathway for Post Radiation or Concurrent Chemo Radiation (RT/CRT) Patient Care for Oropharyngeal Cancer |
Recruiting |
NCT04874493 |
|
|
37 |
A Prospective Cohort Study of Patients With Actinic Keratosis (AK) in the Face or Scalp Treated With Tirbanibulin and Followed for 24 Weeks Post Treatment-initiation. Patient Reported Outcomes (PROs) and Clinical Profile of Patients Will be Gathered for Descriptive Analyses of Patient Outcomes Over the 24-week Study Observation Period |
Recruiting |
NCT05260073 |
|
Tirbanibulin (Klisyri®) |
38 |
Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) |
Recruiting |
NCT03933202 |
|
Cladribine Tablets |
39 |
Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale (PN-PROS) |
Recruiting |
NCT05373979 |
|
|
40 |
Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Injectable DMDs for RMS (CLICK-MS) |
Active, not recruiting |
NCT03933215 |
|
Cladribine Tablets |
41 |
Managed Access Program (MAP) Cohort Treatment Plan CBYL719F12001M to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS) |
Available |
NCT04085653 |
|
alpelisib |
42 |
Pros and Cons of Telemedicine in Diagnosis and Management |
Enrolling by invitation |
NCT04752553 |
|
|
43 |
Health IT Generated PROs to Improve Outcomes in Cirrhosis |
Enrolling by invitation |
NCT03564626 |
|
|
44 |
Evaluation Nationale Des Enfants et Adultes Avec Syndromes d'Hypercroissance Dysharmonieuse National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) |
Not yet recruiting |
NCT05563831 |
|
|
45 |
Before and After Study, Evaluating the Efficiency of an Anticipated Personalization of the Management in Day Hospital Unit Based on a Collection of the PROs Via a Digital Tool |
Not yet recruiting |
NCT05552066 |
|
|
46 |
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway |
No longer available |
NCT03317366 |
|
ARQ 092 |
47 |
HIV + Service Delivery and Telemedicine Through Effective PROs (+STEP) |
Withdrawn |
NCT04489667 |
|
|
|